Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRCA2 Protein”

8 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 8 of 8 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04439227
What this trial is testing

Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 33
Testing effectiveness (Phase 2)Study completedNCT00628251
What this trial is testing

Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer

Who this might be right for
Ovarian Neoplasms
AstraZeneca 97
Testing effectiveness (Phase 2)Study completedNCT00494234
What this trial is testing

Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer

Who this might be right for
Breast Neoplasms
AstraZeneca 54
Early research (Phase 1)Study completedNCT00516373
What this trial is testing

Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

Who this might be right for
Ovarian NeoplasmsBRCA1 ProteinBRCA2 Protein
AstraZeneca 98
Testing effectiveness (Phase 2)Study completedNCT00494442
What this trial is testing

Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer

Who this might be right for
Ovarian Neoplasm
AstraZeneca 58
Not applicableUnknownNCT02959398
What this trial is testing

Evaluation of Tomosynthesis for Characterization and the Management of Breast Lesions

Who this might be right for
Breast NeoplasmsTomosynthesisBRCA1 Protein+1 more
Assistance Publique - Hôpitaux de Paris 2,000
Testing effectiveness (Phase 2)Looking for participantsNCT05485766
What this trial is testing

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast NeoplasmsTriple Negative Breast CancerBreast Neoplasms+5 more
Okayama University 23
Early research (Phase 1)Study completedNCT01286987
What this trial is testing

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Who this might be right for
Advanced or Recurrent Solid TumorsBreast NeoplasmsOvarian Cancer, Epithelial+4 more
Pfizer 113